Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

Baptiste Louveau, Célèste Lebbé, Aurélie Sadoux et al.|Clinical Cancer Research|2021

Cited by 19